Overview

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Status:
Not yet recruiting

Trial end date:
2024-08-27

Target enrollment:

Participant gender:

Summary

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Phase:

Phase 1

Details

Lead Sponsor:

Amgen

Treatments:

Atezolizumab
Carboplatin
Etoposide